المؤلفون: Ailawadhi S; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA., Mikhael JR; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., LaPlant BR; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Laumann KM; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Kumar S; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Roy V; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA., Dingli D; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Bergsagel PL; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Buadi FK; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Rajkumar SV; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Fonseca R; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Kapoor P; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Sher T; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA., Hayman SR; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Stewart AK; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Kyle RA; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Gonsalves WI; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Reeder CB; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Lin Y; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Go RS; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Leung N; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Kourelis T; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Lust JA; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA., Russell SJ; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Chanan-Khan AA; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA., Lacy MQ; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.

المصدر: Leukemia [Leukemia] 2018 Mar; Vol. 32 (3), pp. 719-728. Date of Electronic Publication: 2017 Sep 01.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Drug Resistance, Neoplasm*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Multiple Myeloma/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers, Tumor ; Dexamethasone/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/genetics ; Multiple Myeloma/mortality ; Retreatment ; Survival Analysis ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives ; Treatment Outcome

المؤلفون: Roy V; Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA., Stewart AK; Hematology, Mayo Clinic, Scottsdale, AZ, USA., Bergsagel PL; Hematology, Mayo Clinic, Scottsdale, AZ, USA., Dispenzieri A; Hematology, Mayo Clinic, Rochester, MN, USA., Laumann K; Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA., Allred J; Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Hematology, Mayo Clinic, Rochester, MN, USA., Fonseca R; Hematology, Mayo Clinic, Scottsdale, AZ, USA., Reeder CB; Hematology, Mayo Clinic, Scottsdale, AZ, USA., Kumar S; Hematology, Mayo Clinic, Rochester, MN, USA., Rivera CE; Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA., Gertz MA; Hematology, Mayo Clinic, Rochester, MN, USA., Buadi FK; Hematology, Mayo Clinic, Rochester, MN, USA., Hayman SR; Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Hematology, Mayo Clinic, Rochester, MN, USA.

المصدر: Blood cancer journal [Blood Cancer J] 2015 Mar 20; Vol. 5, pp. e294. Date of Electronic Publication: 2015 Mar 20.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Melphalan/*administration & dosage , Multiple Myeloma/*drug therapy , Prednisone/*administration & dosage , Thalidomide/*analogs & derivatives, Aged ; Aged, 80 and over ; Female ; Humans ; Lenalidomide ; Male ; Melphalan/adverse effects ; Middle Aged ; Multiple Myeloma/pathology ; Prednisone/adverse effects ; Stem Cell Transplantation ; Thalidomide/administration & dosage ; Thalidomide/adverse effects

المؤلفون: Matthews GM; Gene Regulation Laboratory, Cancer Therapeutics, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia. geoff.matthews@petermac.org, Lefebure M, Doyle MA, Shortt J, Ellul J, Chesi M, Banks KM, Vidacs E, Faulkner D, Atadja P, Bergsagel PL, Johnstone RW

المصدر: Cell death & disease [Cell Death Dis] 2013 Sep 12; Vol. 4, pp. e798. Date of Electronic Publication: 2013 Sep 12.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Azacitidine/*therapeutic use , Biphenyl Compounds/*therapeutic use , Histone Deacetylase Inhibitors/*therapeutic use , Multiple Myeloma/*drug therapy , Nitrophenols/*therapeutic use , Sulfonamides/*therapeutic use , TNF-Related Apoptosis-Inducing Ligand/*therapeutic use, Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects ; Azacitidine/pharmacology ; Biphenyl Compounds/pharmacology ; Drug Screening Assays, Antitumor ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Hydroxamic Acids/pharmacology ; Hydroxamic Acids/therapeutic use ; Indoles/pharmacology ; Indoles/therapeutic use ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Multiple Myeloma/metabolism ; Multiple Myeloma/pathology ; Nitrophenols/pharmacology ; Panobinostat ; Piperazines/pharmacology ; Piperazines/therapeutic use ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Proto-Oncogene Proteins c-myc/metabolism ; Receptors, Death Domain/metabolism ; Recombinant Proteins ; Sulfonamides/pharmacology ; TNF-Related Apoptosis-Inducing Ligand/pharmacology

المؤلفون: Lacy MQ; Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. lacy.martha@mayo.edu, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F

المصدر: Leukemia [Leukemia] 2010 Nov; Vol. 24 (11), pp. 1934-9. Date of Electronic Publication: 2010 Sep 09.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Dexamethasone/*administration & dosage , Multiple Myeloma/*drug therapy, Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Disease Progression ; Drug Tolerance ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Risk Assessment ; Survival Rate ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives

المؤلفون: Reeder CB; Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA. Reeder.craig@mayo.edu, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK

المصدر: Leukemia [Leukemia] 2009 Jul; Vol. 23 (7), pp. 1337-41. Date of Electronic Publication: 2009 Feb 19.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Multiple Myeloma/*drug therapy, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Boronic Acids/administration & dosage ; Bortezomib ; Cyclophosphamide/administration & dosage ; Dexamethasone/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/surgery ; Pyrazines/administration & dosage ; Stem Cell Transplantation ; Treatment Outcome

المؤلفون: Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N, Ehlenbeck C, Reeder C, Slack J, Leis JF, Boesiger J, Torloni AS, Fonseca R, Bergsagel PL

المصدر: Leukemia [Leukemia] 2008 Jun; Vol. 22 (6), pp. 1282-4. Date of Electronic Publication: 2008 Jan 24.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Mobilization* , Peripheral Blood Stem Cell Transplantation*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Multiple Myeloma/*therapy, Combined Modality Therapy ; Dexamethasone/administration & dosage ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Lenalidomide ; Remission Induction ; Retrospective Studies ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives ; Treatment Outcome